Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and food-effect study of TAK-438ASA vs vonoprazan + aspirin in healthy Japanese men
jRCT2080223829Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan + aspirin, vonoprazan and aspirin in None (4 arms), sponsored by Takeda. Primary endpoints: Bioequivalence of TAK-438ASA vs vonoprazan + aspirin (pilot and pivotal phases of Study 1) and Food effect on TAK-438ASA pharmacokinetics (Study 2). Started Mar 2018; status: completed.
02
Drugs
vonoprazan + aspirinvonoprazanaspirin
Beyond the preview
Go deeper on jRCT2080223829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223829.